Antibody-based Cancer Therapies
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
6
NCT02844179
(+)-Alpha-Dihydrotetrabenazine Phase I
Phase: Phase 1
Role: Collaborator
Start: Jul 31, 2016
Completion: Jun 27, 2017
Loading map...